Tildrakizumab-Asm 100 mg/mL Suppliers & Bulk Manufacturers

Available Forms: injection (prefilled syringe)

Available Strengths: 100 mg/mL

Reference Brands: Ilumya (USA), Ilumetri (EUUK)

Category: Derma Drugs

Tildrakizumab-asmn is a humanized IgG1/k monoclonal antibody that selectively targets the p19 subunit of interleukin-23 (IL-23). By blocking IL-23 signaling, it reduces inflammation and helps clear plaques in moderate to severe plaque psoriasis. It is prescribed for adults who need systemic therapy or phototherapy. The dosing schedule includes injections at week 0, week 4, and every 12 weeks thereafter. It is administered as a subcutaneous injection under medical supervision.

Product Description:

Tildrakizumab is a monoclonal antibody that binds the p19 subunit of interleukin-23, blocking it from activating its receptor. IL-23 maintains the pathogenic T helper 17 cells that drive plaque psoriasis. Targeting p19 specifically leaves IL-12 untouched, unlike the older agents that blocked the shared p40 subunit, which is thought to explain the clean safety profile of this class.

It is used for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Dosing is unusually infrequent: after initial doses at weeks zero and four, maintenance is once every twelve weeks — four injections a year — which is a meaningful adherence and administration advantage. In trials a large majority of patients reached a seventy-five percent improvement in disease severity, with responses sustained over years. Upper respiratory infections are the most common adverse effect; the class carries a general caution about infection risk and screening for tuberculosis before starting.

Sourcing notes. Originator biologic, on patent, with no biosimilar. Cold chain at 2 to 8°C. Different companies market it in different regions, so the supply route and brand depend on the destination. Prefilled syringe is the standard presentation. Supply is through authorised distribution.